Physician profile
Catherine Lawrence Roach
NPI 1295239770
$5,509.18
in general payments reported to CMS, 2019-2025
28 companies · $1,938 in 2025
The $1,938 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.72 · 2021: $91.79 · 2022: $993 · 2023: $1,213 · 2024: $1,255 · 2025: $1,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,179 · Consulting Fee: $975 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,178.87 |
| Consulting Fee | $975.00 |
| Education | $251.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,237.77 | 2022-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,062.11 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $529.68 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $368.87 | 2023-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $320.27 | 2022-2025 | Ilumya |
| Amgen INC. | $234.59 | 2021-2024 | Otezla |
| Genzyme Corporation | $212.46 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $172.50 | 2022-2025 | Dupixent |
| Merz North America, INC. | $134.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $120.68 | 2023-2025 | |
| Lilly USA, LLC | $117.72 | 2022-2025 | Taltz, Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.34 | 2022-2025 | Spevigo |
| Pfizer INC. | $110.16 | 2022-2024 | |
| Incyte Corporation | $107.39 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $97.84 | 2022-2025 | Adbry |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $92.79 | 2023-2025 | Zoryve |
| Organogenesis INC. | $69.43 | 2025 | Affinity, Apligraf |
| Galderma Laboratories, L.P. | $69.26 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.79 | 2023-2025 | Siliq, Targretin, Cabtreo |
| Biofrontera INC. | $51.51 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $49.66 | 2024 | Vtama |
| Genentech USA, INC. | $43.55 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $31.09 | 2025 | Acthar |
| Organon LLC | $25.77 | 2025 | Hadlima, Vtama |
| Fresenius Kabi USA, LLC | $21.41 | 2024 | Idacio |
| Helsinn Therapeutics (U.S.), INC. | $19.86 | 2022 | |
| Lnhc, INC | $19.31 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $17.14 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.